Fungal Vaccine NXT-2: What Do Gut Safety Tests Show?

What could a vaccine against multiple fungal infections achieve?

The University of Georgia's September 8 announcement highlights NXT-2, a vaccine candidate whose development program has reported protection against several fungal infections in animal models. The latest work addresses another question: whether vaccination disturbs the fungi and bacteria normally present in the digestive tract. Preserving those communities could be an important part of evaluating an intervention intended for people already facing substantial medical risks. [University of Georgia announcement](https://news.uga.edu/fungal-vaccine-and-the-gut/).

Earlier research reported protection against Candida auris in mice, including benefits from administering vaccine-generated antibodies to infected animals. Vaccination and antibody treatment are distinct approaches: vaccination asks the recipient's immune system to generate a response, while antibody treatment supplies part of that response directly. These remain experimental strategies. The university also identifies researcher Karen Norris as the founder and CEO of NXT Biologics, the company developing the vaccine. [University of Georgia research background](https://news.uga.edu/vaccine-protects-against-another-fungal-infection/).

Did NXT-2 leave the gut microbiome completely unchanged?

The study, published in Microbiology Spectrum, assessed Japanese and rhesus macaques receiving two vaccine doses. NXT-2 uses a protein fragment based on KEX1, a target shared across several fungi. Researchers examined stool before vaccination and two weeks after the booster. Fungal community measurements showed no significant changes. However, Japanese macaques had statistically significant changes in some bacterial diversity measures; comparable changes were not detected in rhesus macaques. [Original study](https://journals.asm.org/doi/10.1128/spectrum.01047-26).

No individual bacterial genus changed significantly, and predicted microbial functions remained broadly stable. Nevertheless, the interpretation is narrower than saying the vaccine cannot harm the gut: small animal cohorts and limited sampling cannot establish long-term human safety. In particular, the study did not demonstrate fewer infections in vaccinated patients. The authors identify longer follow-up and assessment in immunocompromised populations as important next steps. [Study findings and limitations](https://journals.asm.org/doi/10.1128/spectrum.01047-26).

Why does fungal prevention matter for public health?

The World Health Organization's first fungal priority pathogens list, published in 2022, identified 19 organisms requiring greater research and public health attention. WHO highlighted antifungal resistance, diagnostic gaps and limited treatment options, and called for stronger surveillance, innovation and prevention. A successful vaccine could contribute to that prevention agenda, although its practical value would depend on which infections it prevents, who responds to it and how long protection lasts. [WHO fungal priority announcement](https://www.who.int/news/item/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi).

Candida auris illustrates the clinical challenge. According to CDC, it can spread in healthcare facilities and cause severe infections, especially among patients with serious underlying conditions or invasive devices such as central lines. Resistance can complicate treatment. People without these risk factors generally do not become ill from this organism, so the research should not be interpreted as evidence that healthy people face an immediate new fungal threat. [CDC overview](https://www.cdc.gov/candida-auris/about/index.html).

For current care, laboratory diagnosis, infection control and appropriate antifungal treatment remain essential. CDC distinguishes infection from colonization, meaning an organism is present without causing illness: Candida auris colonization alone should not receive antifungal treatment. The vaccine findings provide a reason to continue research, while clinical decisions still depend on established evidence and the patient's condition. [CDC clinical guidance](https://www.cdc.gov/candida-auris/hcp/clinical-overview/index.html).